ClinicalTrials.gg
RecruitingNCT07669467NuvastaticTMUpdated Aug 25, 2026

Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer

A Phase 3 interventional study of Nuvastatic 300 and Placebo in Fatigue Related to Cancer Treatment and Breast Cancer, sponsored by Natureceuticals Sdn Bhd. Recruiting at 6 sites in India. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Natureceuticals Sdn Bhd · Phase 3, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2025, registered Jan 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 182 studies in Breast Neoplasms with a site in India — 20 open to participants now, 53 under way, 37 of them phase 3. Breast Neoplasms · India.

Planned enrollment
91st of 161
250 · median 333
Started
2025
with 12 others
Phase 3
84 of 182
11 open now
Primary completion
2026-10
later than 20 of 52 live
Registered
180th of 182
by date

Among the 182 studies in Breast Neoplasms with a site in India, this one is the 91st largest by planned enrollment of the 161 interventional ones that give a count, is one of 13 that started in 2025, is one of 84 in phase 3, reaches primary completion later than 20 of the 52 other live ones, and was the 180th registered.

Breast Neoplasms

14,848 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

20 of the 182 studies in Breast Neoplasms with a site in India are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 182 studies in Breast Neoplasms with a site in India, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether Nuvastatic 300 mg capsules can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy.

The main questions it aims to answer are:

  • Does Nuvastatic 300 mg capsules significantly reduce cancer-related fatigue compared to placebo?
  • Is Nuvastatic 300 mg capsules safe and well tolerated in this patient population?

Researchers will compare Nuvastatic 300 mg capsules vs placebo to see if Nuvastatic 300 capsule improves fatigue scores and maintains an acceptable safety profile.

Participants will:

  • Receive Nuvastatic 300 mg capsules or placebo capsules (3 times per day) for 3 cycles of 20 days each (total \~60 treatment days).
  • Continue their standard first-line chemotherapy regimen.
  • Provide blood sample assessments at Screening and End of Treatment.
  • Complete patient diaries and fatigue assessments as per protocol.
03

Conditions studied

  • Fatigue Related to Cancer Treatment
  • Breast Cancer

Browse trials for

Keywords

  • Nuvastatic
  • Breast Cancer
  • Cancer related fatigue
  • Randomized double blind placebo controlled trail
  • First-Line Chemotherapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged ≥ 18 years and ≤ 65 years who are willing to voluntarily provide consent for participation in the study.
  • Patients with confirmed triple negative breast cancer who are planned or scheduled to receive standard chemotherapy treatment for at least 4 to 6 cycles respectively.
  • Patients must have a confirmed diagnosis of triple negative metastatic breast cancer as per standard guidelines.
  • Patients must have at least one tumour lesion with ≥ 1cm in one dimension that is radiographically apparent on computed tomography (CT) or magnetic resonance imaging (MRI).
  • (ECOG) performance status of 0-2 at screening.
  • The patient has stable (≥ 9 g/dL) throughout the screening.
  • ≥ 6 months, as per the investigator's judgment.
  • Patients with co-morbidities or medical conditions including Type 2 diabetes mellitus (DM) and hypertension who are deemed stable by the investigator can be included in the study.
  • At screening, patients with stable fatigue, newly developed fatigue, or worsening fatigue scores as assessed by the Brief Fatigue Inventory (BFI) should be included.

Exclusion criteria

Exclusion Criteria:

  • Patients who have any untreated reversible medical condition which may cause fatigue (e.g. major metabolic or electrolyte disturbance, active infection, endocrine abnormalities) as per the investigator's clinical judgment.
  • Patients with an inability to understand local language(s) for scales used for evaluations i.e. VAFS, BFI AND SF-36.
  • Patients who have received concurrent stimulant medication (e.g. dextroamphetamine or methylphenidate) during the screening period or any medication which may interfere with the study drug.
  • Patients with any delay in chemotherapy treatment such that the screening period extends beyond 21 days.
  • Patients with known central nervous system (CNS) involvement.
  • Patients with any serious, uncontrolled, non-malignant medical or psychiatric disorder, or any other medical condition which in the opinion of the investigator, may affect the patient's safety or study participation and conduct.
  • Female patients who are pregnant or breastfeeding.
  • Patients with known virus, virus, infection.
  • Patients who have nausea and vomiting or any gastrointestinal disorder that is severe enough to interfere with study drug absorption in the opinion of the investigator.
  • Patients with uncontrolled pain, who in the opinion of the investigator are not eligible for the study.
  • Patients with known or intolerance of rosmarinic acid, caffeic acid, and other related phenolic compounds as well as in the Nuvastatic® 300 mg or placebo treatment.
  • Patients with planned therapy or treatment with another agent.
  • Previous exposure to any investigational agent within 4 weeks prior to screening, or planned administration of an investigational agent, other than as specified by this protocol, during the study period.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
250 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo capsule

    Drug: Placebo

  • Experimental
    Nuvastatic 300

    Nuvastatic™ 300 capsule

    Drug: Nuvastatic 300

Interventions

  • DrugNuvastatic 300

    300mg capsule, (3 capsules X 3 times a day)

  • DrugPlacebo

    300mg capsule, (3 capsules X 3 times a day)

06

What researchers measure

Primary outcomes

  1. Reduction in cancer-related fatigue in breast cancer patients undergoing first-line chemotherapy, assessed after treatment with Nuvastatic versus placebo.

    The primary outcome measure is the intra-individual changes in the Brief Fatigue Inventory (BFI) fatigue scale.

    Time frame: From Screening to EOT (about 6 months)

Secondary outcomes

  1. Overall QoL and functional improvement

    The secondary outcome measure is the overall QoL improvement using the medical outcome scale Short Form-36 (SF-36).

    Time frame: at baseline and at end of the study (about 6 months)

  2. Overall QoL and functional improvement

    The secondary outcome measure is the overall QoL improvement using the ECOG scores that will be compared at baseline and at end of the study.

    Time frame: At baseline and at end of the study (about 6 months)

  3. Reduction in cancer-related fatigue in breast cancer patients undergoing first-line chemotherapy, assessed after treatment with Nuvastatic versus placebo.

    The primary outcome measure is the intra-individual changes in the Visual Analogue Fatigue Scale (VAFS).

    Time frame: From Screening to EOT (about 6 months)

07

Study locations

3 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 12 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2026
First posted
Jun 25, 2026
StartActual
Oct 1, 2025
Primary completionEst.
Oct 30, 2026
CompletionEst.
Oct 30, 2026
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07669467
Responsible party
Sponsor
First posted
Jun 25, 2026
Start date
Oct 1, 2025
Primary completion
Oct 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Aug 25, 2026

Study contacts

Aman Shah Abdul Majid, MBChB, DPhil
Contact
amanharvard2020@outlook.com
+605-2490500

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion